Phase III
The company announced positive data from the Phase III KEYNOTE-355 trial looking at Keytruda in combination with chemotherapy as first-line treatment for metastatic triple-negative breast cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
They expect to share the complete findings with regulators in the upcoming months and make a final decision on whether to continue the clinical trial.
The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of this year, with plans, if approved, to launch the drug in the fourth quarter of 2021.
In Phase III EXPLORER-HCM clinical trial, mavacamten demonstrated a robust treatment effect and met all primary and secondary endpoints.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
The therapy is being developed to decrease C. difficile (C. diff) infection recurrences.
PRESS RELEASES